The CRISPR Cas patent files, part 3: Prime Editing and integrase-based variants

IF 3.9 2区生物学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Journal of biotechnology Pub Date : 2025-07-12 DOI:10.1016/j.jbiotec.2025.07.006

Ulrich Storz

引用次数: 0

Abstract

The epic patent disputes regarding CRISPR Cas9 and, to a lesser extent, CRISPR Cas12a, have somehow overcast a new patent debate that is materializing at the horizon, namely the one that relates to Prime Editing and its integrase-based siblings. While these techniques offer great promise for the precise integration of large DNA stretches into a host genome, it appears that a new chain of dependencies is about to unfold that makes the establishment of Freedom to Operate complicated for interested parties. (Arnold, 2024).

查看原文本刊更多论文

CRISPR Cas专利文件，第3部分：主要编辑和基于整合酶的变体

关于CRISPR Cas9和CRISPR Cas12a（在较小程度上）的史诗级专利纠纷，在某种程度上掩盖了即将出现的一场新的专利辩论，即与Prime编辑及其基于整合酶的兄弟姐妹有关的专利辩论。虽然这些技术为将大DNA片段精确整合到宿主基因组中提供了巨大的希望，但似乎一个新的依赖链即将展开，这使得对相关方来说，建立“操作自由”变得更加复杂。(阿诺德,2024)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of biotechnology 工程技术-生物工程与应用微生物

CiteScore

8.90

自引率

2.40%

发文量

190

审稿时长

45 days

期刊介绍： The Journal of Biotechnology has an open access mirror journal, the Journal of Biotechnology: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review. The Journal provides a medium for the rapid publication of both full-length articles and short communications on novel and innovative aspects of biotechnology. The Journal will accept papers ranging from genetic or molecular biological positions to those covering biochemical, chemical or bioprocess engineering aspects as well as computer application of new software concepts, provided that in each case the material is directly relevant to biotechnological systems. Papers presenting information of a multidisciplinary nature that would not be suitable for publication in a journal devoted to a single discipline, are particularly welcome.